Cosmetic vs OTC Drug: How to Get FDA GMP Compliant

Most cosmetic brands don't decide to become drug manufacturers. It happens on a product page, a social media caption, or a formulation sheet, and nobody notices until FDA sends a warning letter or a retailer asks for a Drug Facts label. If that has just happened to you, or you suspect it might, this article walks through what changed, what it means, and how to get to a defensible compliance position.

I'm Jared Clark, and I work with companies in exactly this spot. The good news is that the path is well defined. The uncomfortable part is that it is usually longer than the founders expect, because drug status brings an entire quality system with it.

How Does FDA Decide a Cosmetic Is Actually a Drug?

FDA does not classify products by what the label category says. It classifies them by intended use. Under section 201(i) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), a cosmetic is an article intended to be rubbed, poured, sprinkled, or sprayed on the body for cleansing, beautifying, promoting attractiveness, or altering the appearance. Under section 201(g)(1), a drug is an article intended to diagnose, cure, mitigate, treat, or prevent disease, or intended to affect the structure or any function of the body.

In practice, a product becomes a drug in FDA's eyes through one or more of these routes:

• Claims. "Reduces acne breakouts," "repairs damaged skin barrier at the cellular level," "stimulates collagen production," "prevents hair loss," "protects against sun damage."
• Ingredients. An active ingredient that only makes sense for a drug purpose, such as a sunscreen active, salicylic acid for acne, or fluoride in a toothpaste.
• Consumer perception and context. Website copy, testimonials, influencer posts, and even the product name can establish intended use.
• Product type. Sunscreens, antiperspirants, anti-dandruff shampoos, and anticavity toothpastes are drugs by definition when they make those claims.

Products that do both, such as a moisturizer with SPF or a shampoo that also treats dandruff, are regulated as both a cosmetic and a drug. FDA's own consumer page, "Is It a Cosmetic, a Drug, or Both?", makes this point directly, and the drug requirements apply in full to the drug side of that overlap.

The most common trigger I see is not the label at all. It is the marketing copy that grew around the product after launch.

Cosmetic Claims vs. Drug Claims

The right column is where intended use shifts. Notice that the difference is often one verb. This table is illustrative, not a safe-harbor list: FDA judges intended use on the whole context, so a "cosmetic" phrase such as "cleanses pores" can still support drug status if the surrounding claims, ingredients, or imagery point to treating acne.

What Changes When Your Product Is an OTC Drug?

Here is the side-by-side comparison of what each category requires. It is the single fastest way to see the size of the gap.

The MoCRA entries in this table reflect the status as of this article's date (2026-09-29). The cosmetic GMP rule and the registration exemptions may change, so confirm them against FDA's MoCRA webpage before relying on them.

Two consequences of that table deserve plain language. First, a drug that is not made in conformance with current good manufacturing practice is adulterated under section 501(a)(2)(B) of the FD&C Act, regardless of whether the finished product is perfectly safe. Second, a product marketed with drug claims that meets neither a monograph nor holds an approval is an unapproved new drug under section 505(a). Either one is a prohibited act under section 301.

MoCRA added new obligations for cosmetics in chapter VI of the FD&C Act, but it did not amend the definitions in sections 201(i) and 201(g)(1) that set the line between cosmetic and drug. If you are a drug, the drug rules govern, and a cosmetic-only compliance program does not cover the drug portion of the product.

What Are Your Options When FDA Treats Your Cosmetic as a Drug?

You have two real paths, and it is worth choosing deliberately instead of drifting into one.

Path 1: Become a compliant OTC drug. This makes sense if the drug claim is a core part of the product's value, such as an SPF product, an acne treatment, or an anti-dandruff shampoo. You keep the claims, and you build the quality system and regulatory file to support them.

Path 2: Remove the drug claims and go back to cosmetic status. This can work when the claims crept in through marketing and the formulation was never meant to treat anything. It requires scrubbing every channel: the label, the website, social media, sell sheets, retailer listings, and third-party reviews you republish. This path is often underestimated, because FDA looks at the whole record of intended use, not just the label. Removing claims also does not fix a product whose active ingredient is a drug active, as discussed next.

A middle situation I see often is a product with a legitimate active ingredient that the brand did not realize was a drug active. There, removing the claim is not enough, because the ingredient itself signals drug intent. Reformulating may be the only clean exit.

Whichever path you pick, if FDA has already contacted you, your written response should say which path you chose and give dates. Vague promises to "review our practices" tend to prolong the conversation.

How Does the OTC Monograph Pathway Work?

Most OTC drugs are marketed without an individual FDA approval because they conform to a monograph. The CARES Act of 2020 reformed this system by creating section 505G of the FD&C Act, under which monograph drugs are deemed generally recognized as safe and effective (GRASE) when they meet the conditions of the applicable monograph, which are now issued as administrative orders rather than through lengthy notice-and-comment rulemaking.

For a product to sit inside a monograph, all of the following generally need to line up:

1. The active ingredient is listed in the monograph for the claimed use.
2. The concentration and dosage form are within the monograph conditions.
3. The labeling uses the permitted indications and required warnings.
4. The general conditions for OTC drugs are met, including the labeling and formulation conditions in 21 CFR 330.1.
5. The product is manufactured in compliance with cGMP.

If your active, claim, or dosage form falls outside a monograph, the pathway is not a small tweak. It typically means an NDA or another application route, and that changes the timeline and cost by orders of magnitude. Better to find that out before you have inventory sitting in a warehouse.

Step-by-Step: How to Get Compliant as an OTC Drug Manufacturer

This is the sequence I use with clients. Steps overlap in real life, but the order matters, because later steps depend on earlier decisions.

Step 1: Classify each product honestly

Build a product inventory with one row per SKU. For each, record the active ingredients, every claim in every channel, the dosage form, and the applicable monograph or application. Do this before you touch anything else. The exercise usually surfaces two or three products that nobody realized were drugs.

Step 2: Sort out who is making the product

Decide whether you are the manufacturer, a contract manufacturer is, or both. Registration and listing obligations follow the establishment. Owners of the label and firms that manufacture, repack, or relabel each have responsibilities, and your quality agreements need to say who does what. If you rely on a contract manufacturer, confirm that they are registered, have a current cGMP history, and can actually run drug batch records. Many cosmetic contractors cannot.

Step 3: Register the establishment and list the drug

Under section 510 and 21 CFR Part 207, drug establishments register with FDA and list their drug products through the electronic submission process. Listing includes a labeler code and National Drug Code for each product. Your NDC and barcode formatting decisions carry downstream effects, so see our guide on NDC format and drug label barcode requirements before you finalize packaging artwork. Also confirm your facility's OMUFA fee obligations, because unpaid fees can put a facility on FDA's arrears list, which carries its own consequences.

Step 4: Convert the label to Drug Facts

21 CFR 201.66 prescribes the Drug Facts format: active ingredients with amounts, purpose, uses, warnings, directions, other information, inactive ingredients, and a questions line. Section 502(x) of the FD&C Act also requires a domestic address or phone number on the label so consumers can report serious adverse events. Redesigning packaging takes longer than most teams plan for, so start this early.

Step 5: Build the quality system around 21 CFR Part 211

This is the largest workstream, and it is where cosmetic operations usually feel the difference most. At a minimum you need the following:

For the training row, see our overview of GMP training requirements for manufacturing staff for how to structure it.

I would not attempt all of these at once. Start with the quality unit, the batch record, and the component controls, because those are the items an investigator asks for first.

Step 6: Control components and suppliers

Under 21 CFR 211.84(d)(2), at least one specific identity test is required for each component lot. A supplier's certificate of analysis can be relied on for other tests only if you have established the supplier's reliability through periodic validation of their results. That means establishing and periodically validating supplier reliability is a requirement for drugs, not an optional best practice.

High-risk components deserve special attention. FDA's guidance "Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol" exists because contaminated excipients have caused deaths, including the 1937 Elixir Sulfanilamide poisonings in the United States and the 1990s diethylene glycol poisonings of children in Haiti. Many topical products contain glycerin or propylene glycol, so this applies to formulas that once felt harmless.

Step 7: Set up stability and expiration dating

21 CFR 211.166 requires a written stability testing program, and 21 CFR 211.137 addresses expiration dating. Sunscreens and active-containing topicals need stability data that supports the shelf life on the label, including container-closure interaction. Cosmetic-era "best by" assumptions rarely hold up under an investigator's questions.

Step 8: Stand up complaint handling and adverse event reporting

21 CFR 211.198 requires written procedures for handling complaints, with quality unit review and investigation records. Separately, section 760 requires the responsible person for a nonprescription drug marketed without an approved application to submit serious adverse event reports to FDA within 15 business days of receiving the report, and you need to keep records of all adverse events for the required retention period. Decide now who receives complaints, who triages them, and who files the report. This often falls through the cracks when the customer service inbox belongs to marketing.

Step 9: Prove it works with internal audits and mock inspection

Before FDA arrives, audit yourself against Part 211. FDA drug inspections generally follow a systems-based approach, so walk your own facility the same way: quality, facilities and equipment, materials, production, packaging and labeling, and laboratory controls. Our page on FDA inspection preparation lays out the approach in more detail, and if you want the wider picture of what a first drug-side program looks like, the OTC drug manufacturing overview is a good starting point.

What Does a Realistic Timeline Look Like?

Timelines depend on how far your existing operation is from Part 211. The ranges below are the author's planning figures, not regulatory deadlines. They assume an existing, suitable facility, a product that fits an OTC monograph (no NDA), and a small product line. Phases overlap deliberately. A full Part 211 build-out plus label conversion can take longer than 20 weeks.

If you have already received a warning letter, the letter typically asks for a response within 15 business days (a standard FDA request, not a regulatory deadline), which will compress everything, and your first job is a credible written response with commitments you can keep. For a sequenced approach, see setting up a GMP quality system for OTC monograph topical products.

Common Mistakes That Extend the Timeline

Treating the label as the whole problem. Intended use lives in the website, the social feed, the sales deck, and the influencer contract. Fix the label and leave the Instagram bio, and the problem remains.

Assuming a cosmetic contract manufacturer can make a drug. Some can. Many run without a quality unit independent of production, without batch record review, and without identity testing. Ask for their last FDA inspection history and a sample batch record before you sign anything.

Skipping identity testing because the supplier's paperwork looks fine. The certificate of analysis does not replace the identity test required by 21 CFR 211.84(d)(2).

Building SOPs nobody uses. An investigator will compare the procedure to what operators do on the floor. A shorter procedure people follow beats a long one they don't.

Ignoring adverse event handling until the first complaint. By then the clock is already running.

Where I Would Start This Week

If I were in your seat today, I would do three things before anything else. Pull every claim you have published for each product and read it as an FDA reviewer would. Decide whether the drug claim is worth keeping. Then, if it is, find out whether your manufacturing site can actually run a Part 211 batch, because that answer determines your budget and your calendar more than any other.

Nobody enjoys learning their product has been a drug all along. But the companies that come through this well treat it as a decision with a clear owner, a chosen path, and dated commitments, not a paperwork exercise.

If you want a second set of eyes on your classification or your gap assessment, you can reach me through Certify Consulting.

Last updated: 2026-09-29

Frequently Asked Questions

How do I know if my cosmetic is legally an OTC drug?

FDA looks at intended use under FD&C Act section 201(g)(1) and 201(i). If your label, website, social media, or ingredients show the product is meant to treat or prevent disease or affect the structure or function of the body (for example, treating acne, preventing sunburn, or stopping dandruff), FDA treats it as a drug. Products that do both are regulated as both a cosmetic and a drug.

What GMP regulations apply to OTC drugs?

OTC drugs must be manufactured under 21 CFR Part 210 and Part 211, the current good manufacturing practice regulations for finished pharmaceuticals. A drug not made in conformance with cGMP is adulterated under FD&C Act section 501(a)(2)(B), even if the finished product tests fine.

Do cosmetic GMP rules under MoCRA satisfy drug GMP requirements?

No. If the product is a drug, the drug cGMP requirements in 21 CFR Parts 210 and 211 apply. MoCRA added cosmetic obligations but, as I read it, did not change where the line between cosmetic and drug sits, so a cosmetic-only program should not be relied on to cover the drug side.

Do I need FDA approval to sell an OTC drug?

Not always. Under FD&C Act section 505G, a monograph drug can be marketed without individual approval if it meets the applicable monograph conditions, including active ingredient, concentration, labeling, and cGMP. Products that fall outside a monograph generally need an approved application, such as an NDA.

What label do OTC drugs need?

OTC drugs use the Drug Facts format required by 21 CFR 201.66, which lists active ingredients, purpose, uses, warnings, directions, other information, inactive ingredients, and a questions line. Section 502(x) also requires a domestic address or phone number for reporting serious adverse events.